Marché des médicaments contre la leucémie myéloïde aiguë au Pérou – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et perspectives du marché des médicaments contre la leucémie myéloïde aiguë au Pérou

La leucémie myéloïde aiguë (LMA) est un type de cancer du sang qui affecte la moelle osseuse . Chez l'adulte, c'est le type de leucémie aiguë le plus fréquent. S'il n'est pas traité, ce type de cancer s'aggrave généralement rapidement. La LMA est un type de leucémie qui affecte les cellules sanguines.

Les cellules souches sanguines (cellules immatures) sont produites dans la moelle osseuse et deviennent matures au fil du temps. Une cellule souche sanguine peut se différencier en cellule souche myéloïde ou lymphoïde. Un globule blanc se développe à partir d'une cellule souche lymphoïde. Une cellule sanguine mature issue d'une cellule souche myéloïde est l'un des trois types suivants : les globules rouges, les granulocytes et les plaquettes.

Les médicaments contre la leucémie myéloïde aiguë sont de soutien et visent à réduire la gravité des symptômes. Data Bridge Market Research analyse que le marché péruvien des médicaments contre la leucémie myéloïde aiguë connaîtra un TCAC de 6,5 % au cours de la période de prévision de 2022 à 2029.

Peru Acute Myeloid Leukemia Drugs Market Dynamics

Drivers

• Rising Burden of Acute Myeloid Leukemia

The rising burden of cancer cases is one of the major boost of acute myeloid leukemia drugs. As increase in cancer cases leads to increase in demand for the treatment.

For instance,

• In Peru, the deaths attributed to cancer increased from 15.4% of all deaths in 2003 to 18.1% in 2016 (p<0.001)
• Between the years 2003 and 2016, almost one fifth of deaths were attributed to cancer in Peru

From the above point we can conclude that the incidence of acute myeloid leukemia is increasing rapidly in Peru and Ecuador, as a result the market of acute myeloid leukemia drugs market is also increasing. The reason of increasing cancer cases can include several factors such as changing lifestyles and environmental changes, which are expected to further boost the market growth.

• Rising Clinical Trials and Product Approval

Rising clinical trials is one of the major driver points for the market. As more clinical trials will be done, chances of new drugs approval will increase.

For instance,

• In Peru, from 1995 to 2019, 1996 clinical trials were done and 23.5% of them are oncological trials
• The number of oncological trials is increasing over the years with different characteristics

From the above points we can established that oncological trials are increasing in Peru and Ecuador over the years which is expected to drive the growth of the acute myeloid leukemia drugs market.

Opportunities

Strategic Initiatives by Market Players

The need for medications for treatment of acute myeloid leukemia in Peru and Ecuador has increased due to the rise in prevalence of acute myeloid leukemia, advanced therapies for treatment of leukemia and oncology being the largest therapeutic market with unmet medical needs. These factors enhance the necessity for chemotherapy and immunotherapy and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

• In June 2020, AbbVie Inc., received the Food and Drug (FDA) approval for Venclexta (venetoclax), for the overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. Venclexta received approval, in combination with azacitidine, for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Approval was also granted in Mexico, Israel, Puerto Rico and Peru. The approval gained had ensured post marketing rights of venetoclax in Peru and its clinical use in cancer research hospitals, situated in Peru and Ecuador

Rise of Innovative Therapies

Relapse continues to be a major issue in providing cure in patients with acute myeloid leukemia (AML). The outcome after relapse is not uniform in all patients with AML and is dependent on several factors, such as age, genetic profile, cytogenetics at initial diagnosis, duration of first complete remissions. Hence, to overcome the hurdles, innovative therapies are required, with treatment strategies based on identification of specific targets and methods to overcome these aberrant processes.

For instance,

• In June 2021, Bristol Myers Squibb received the approval for Onureg (azacitidine tablets). Onureg is the first oral maintenance innovative therapy, for patients with a broad range of acute myeloid leukemia (AML) subtypes

The use of innovative therapies is expected to improve diagnosis, risk stratification, and disease monitoring of acute myeloid leukemia. The innovative combined drug therapies are expected to patient outcomes in the coming years. Hence, the use of innovative therapies is expected to create lucrative opportunity for the Peru and Ecuador acute myeloid leukemia drugs market.

Restraints/Challenges

However, high cost associated with the available and lack of infrastructure in low-income countries will impede the growth rate of Peru acute myeloid leukemia drugs market. Additionally, the risks incurred while using the orthotic devices will hinder the Peru acute myeloid leukemia drugs market growth. The adverse effects associated with cancer drugs and less expertise will further challenge the market in the forecast period mentioned above.

The Peru acute myeloid leukemia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Peru acute myeloid leukemia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Peru acute myeloid leukemia drugs is a chronic foot disorder that is relatively uncommon and whose incidence is unknown. The study by the Science Direct, states that the incidence of acute myeloid leukemia in Peru is 4.79 AML cases per 100,000 habitants, with the highest incidence rate observed in Piura (a coastal city in Northern Peru) with 38 AML cases per 100,000 habitants.

Peru acute myeloid leukemia drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Covid-19 Impact on the Peru Acute Myeloid Leukemia Drugs Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to health-care facilities for routine and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in the chemotherapy medication adherence during the pandemic.

Recent Development

• In June 2021, Bristol Myers Squibb had received approval from European Commission for Onureg. Onureg is used as a Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia. The approval received would ensure post marketing approval in the U.S., Europe and South America region. Onureg is expected to increase the sales and product revenue in Ecuador and Peru, thereby increasing the market growth

Peru Acute Myeloid Leukemia Drugs Market Scope

The Peru acute myeloid leukemia drugs market is segmented on the basis of sub-type, drugs, drug type, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyze growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Sub-Type

• M3 (Acute Promyelocytic Leukemia (Apl))
• M2 (Acute Myeloblastic Leukemia With Maturation)
• M4 (Acute Myelomonocytic Leukemia)
• M0 (Undifferentiated Acute Myelobastic Leukemia)
• M1 (Acute Myeloblastic Leukemia With Minimal Maturation)
• M5 (Acute Monocytic Leukemia)
• M7 (Acute Megakaryoblastic Leukemia)
• M6 (Acute Erythroid Leukemia)

On the basis of sub-type, the market is segmented into M0 (undifferentiated acute myelobastic leukemia), M1 (acute myeloblastic leukemia with minimal maturation), M2 (acute myeloblastic leukemia with maturation), M3 (acute promyelocytic leukemia (APL)), M4 (acute myelomonocytic leukemia), M5 (acute monocytic leukemia), M6 (acute erythroid leukemia), M7 (acute megakaryoblastic leukemia).

Drugs

• Chemotherapy
• Targeted Therapy
• Immunotherapy

On the basis of drugs, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others. The chemotherapy is sub-segmented into cytosar, daunorubicin doxorubicin, methotrexate, decitabin, cladribine and others. The targeted therapy is sub segmented into venetoclax (venclexta), midostaurin (rydapt), enasidenib (idhifa) and others. The immunotherapy is sub-segmented into obinutuzumab (gazyva/gazyvaro), rituximab, interferons, alemtuzumab (campath) and others.

Drug Type

• Branded
• Generics

On the basis of drug type, the market is segmented into branded and generics. The branded segment is sub-segmented into cytosar, venclexta, rydapt, idhifa, gazyva/gazyvaro, campath and others.

 Route of Administration

• Oral
• Parenteral
• Others

On the basis of route of administration, the Peru acute myeloid leukemia drugs market is segmented into oral, parenteral and others. The oral segment is sub-segmented into tablet, capsule and others. The parenteral segment is further sub-segmented into subcutaneous, intravenous and others

Population Type

• Adult
• Geriatric
• Pediatric

On the basis of population type, the Peru acute myeloid leukemia drugs market is segmented into pediatric, adult and geriatric. The adults is sub-segmented into male and female.

End User

• Hospitals
• Specialty Clinics
• Ambulatory Centers
• Others

On the basis of end user, the Peru acute myeloid leukemia drugs market is segmented into hospitals, specialty clinics, ambulatory centers and others.

Distribution Channel

• Direct Sales
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the Peru acute myeloid leukemia drugs market is segmented into direct sales, hospital pharmacy, retail pharmacy, online pharmacy and others.

Pipeline Analysis (not provided)

• Cytarabine (Phase III)
• BI 836858 (Phase II)
• AZD5991, with Venetoclax (Phase II)
• AZD5991 (Phase I)
• CC-95251 (Phase I)
• Decitabine (Phase I)
• MK-0482 (Phase I)

Peru Acute Myeloid Leukemia Drugs Market Regional Analysis/Insights

The Peru acute myeloid leukemia drugs market is analysed and market size insights and trends are provided by country sub-type, drugs, drug type, route of administration, population type, end user, and distribution channel as referenced above.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché qui ont un impact sur les tendances actuelles et futures du marché. Les points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation, sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la forte concurrence des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché des médicaments contre la leucémie myéloïde aiguë au Pérou

Le paysage concurrentiel du marché des médicaments contre la leucémie myéloïde aiguë au Pérou fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché des médicaments contre la leucémie myéloïde aiguë au Pérou.

Français Certains des principaux acteurs opérant sur le marché péruvien des médicaments contre la leucémie myéloïde aiguë sont Pfizer Inc., MERCK SHARP & DOHME CORP. (UNE FILIALE DE MERCK & CO., INC.), Janssen Pharmaceuticals, Inc. (UNE FILIALE DE Johnson & Johnson Services, Inc.), Novartis AG, Fresenius Kabi AG, F. Hoffmann-La Roche Ltd, Abbvie Inc, Novartis Ag, F. Hoffmann-La Roche Ltd, AstraZeneca, Bohringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., et d'autres.

SKU-68062